EMA revokes eight class waivers for PIPs to 'encourage' development of drugs for children
This article was originally published in SRA
Executive Summary
The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.